For MIBC, the inhibition of immune checkpoints such as programmed cell death ligand 1 (PD‐L1)/programmed cell death protein 1 (PD‐1) can reactivate immune cells cytotoxicity and cause tumor regression.6 Additionally, several immune checkpoint inhibitors (ICIs) such as atezolizumab (PD‐L1 inhibitor) and nivolumab (PD‐1 inhibitor) were approved by the Food and Drug Administration (FDA) for curing advanced MIBC, and they significantly prolong the survival time of advanced MIBC patients.7, 8. Here, PDCD1 is linked to neoplasm.